ClinicalTrials.gg
Not yet recruitingNCT07889362Updated Oct 22, 2026

A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)

A Phase 2 interventional study of Felzartamab in Immunoglobulin A Nephropathy, sponsored by Biogen. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

Updated Oct 22, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caused by the buildup of an antibody called IgA in the kidneys over time. In people with IgAN, abnormal IgA and other antibodies form clusters that build up in the small filters of the kidneys, which leads to inflammation and damage. Felzartamab is designed to target certain immune cells that produce these abnormal antibodies.

The main goal of the study is to learn about the effect felzartamab has on the buildup of IgA clusters in the kidneys. The main question that researchers want to answer is:

  • How much does the buildup of IgA in the kidney change from the start of the study to Week 36? Researchers will also learn about the effect felzartamab has on kidney health by measuring protein levels in the urine and the kidneys' ability to filter blood. They will also learn more about the safety of felzartamab and how the body processes the drug.

The study will be done as follows:

  • Participants will be screened to check if they can join the study.
  • This is an open-label study, which means both the researchers and the participants will know that all participants are receiving felzartamab.
  • Participants will receive felzartamab as intravenous (IV) infusions.
  • Participants will have kidney biopsies done over the course of the study to help measure changes in the health of the kidneys.
  • Participants will have multiple scheduled study visits over about 104 weeks. An extra study visit may be needed if a participant decides to leave the study early.
  • In total, participants will stay in the study for about 2 years (up to 112 weeks).
Read the detailed description

The primary objective of the study is to evaluate the effects of felzartamab on immunoglobulin A (IgA) deposition by immunofluorescence (IF). The secondary objectives are to evaluate the effects of felzartamab on histological and efficacy endpoints, and to evaluate the safety, pharmacokinetics (PK), and immunogenicity of felzartamab.

02

Conditions studied

  • Immunoglobulin A Nephropathy

Keywords

  • Felzartamab
  • Biopsy
03

In context

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

This study's planned enrollment of 25 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.

Browse Glomerulonephritis, IGA studies →

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • -confirmed diagnosis of IgAN.

Key Exclusion Criteria:

  • Conditions that may predispose to an increased bleeding risk, as determined by the Investigator.
  • History of diabetes mellitus.
  • Any diagnosed or suspected or immunodeficient state.
  • Any history of within 5 years prior to Screening with the exception of adequately treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma or other non-melanomatous skin cancer.
  • Any underlying illness that, in the opinion of the Investigator, medical monitor, and/or Sponsor may compromise study participation, present a safety risk to the participant, or may confound the interpretation of the study results, including general non-adherence to study medication therapy.
  • Active clinically significant infections; known history of recurrent clinically significant infection.
  • Hematologic and hepatic abnormalities.
  • History of major surgery, severe trauma, or bone fracture within 3 months prior to first dose of felzartamab or planned major surgery any time from Screening until 1 month after the end of study.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Felzartamab

    Participants will receive a single dose of felzartamab at each dosing visit.

    Drug: Felzartamab

Interventions

  • Administered IV

    Also known as: BIIB148, MOR202, MOR03087, TJ202

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mesangial Immunoglobulin A (IgA) Deposition by Immunofluorescence (IF)

    Time frame: Baseline, Week 36

Secondary outcomes

  1. Change From Baseline in Mesangial IgA Deposition by IF

    Time frame: Baseline, Week 104

  2. Percent Change From Baseline in Proteinuria

    Time frame: Baseline up to Week 36

  3. Annualized Rate of Change (slope) in the Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Baseline up to Week 104

  4. Change From Baseline in eGFR

    Time frame: Baseline up to Week 104

  5. Percentage of Participants Achieving Complete Response (CR)

    Time frame: Baseline up to Week 104

  6. Percentage of Participants who Progressed to Kidney Failure

    Time frame: Baseline up to Week 104

  7. Percentage of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE)

    Time frame: Baseline up to Week 104

  8. Number of Participants with Clinically Significant Laboratory, Physical Examination, Vital Signs and Electrocardiograms (ECGs) Abnormalities

    Time frame: Baseline up to Week 104

  9. Felzartamab Serum Concentrations Over Time

    Time frame: Predose and at multiple timepoints postdose up to Week 36

  10. Number of Participants with Anti-Drug Antibodies (ADAs) Against Felzartamab

    Time frame: Baseline up to Week 104

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2028, 20 months later.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2026
First posted
Oct 22, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Aug 13, 2028
CompletionEst.
Dec 2, 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07889362
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Aug 13, 2028 (estimated)
Completion
Dec 2, 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Felzartamab

Start the discussion